A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

Summary

The goal of this clinical research study is to evaluate how well ferumoxtran-10, a new Magnetic Resonance Imaging (MRI) contrast agent, can detect cancer in the pelvic lymph nodes or malignant pelvic lymph nodes.

Timeline

Start

2005-07

Primary completion

2007-01

Completion

2007-01

Outcome

Outcome not reported

Stopped: “Terminated at request of sponsor.”

Drugs

Indications